Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) (“Shanghai Fosun Pharmaceutical”) and Fosun International have confirmed that the 2025 H Share RSU Scheme and the Conditional H Share RSU Grant, approved at their respective general meetings on 23 October 2025, have proceeded with a first grant of 10,589,500 RSUs on 4 November 2025. The number of grantees has been reduced to 195 from 201 following the departure of six proposed grantees.

The total RSUs allocated under this first grant amount to 10,589,500, comprising 953,500 RSUs for the chairman, 686,500 RSUs each for two other executive board members, 610,200 RSUs for one executive director, 50,900 RSUs for the employee director, 762,800 RSUs for the chief executive officer, and 6,839,100 RSUs for 189 other eligible participants. The H Share RSU Grant Date has been designated as 4 November 2025, with a closing price of HK$22.62 per H Share on that day.

The H Share Scheme Mandate Limit allows for up to 54,097,150 H Shares (representing approximately 10% of the Company’s H Shares in issue, excluding any treasury shares). After the first grant of 10,589,500 RSUs, 43,507,650 H Shares remain available for future allocation. The announcement clarifies that no financial assistance has been provided by Shanghai Fosun Pharmaceutical or its subsidiaries to facilitate the participants’ acquisition of H Shares under the scheme. No other changes have been made to the original terms of the H Share RSU First Grant.